AOAnna Ong-Lim

Anna Ong-Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Ong-Lim has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Alejandro Macias

    Universidad de Guanajuato, Leon Gto, Mexico

    2 shared publications
  • Cao Huu Nghia

    Institute Pasteur, Ho Chi Minh City, Vietnam

    2 shared publications
  • Carlos Alvarez-Moreno

    Infectious Diseases Unit, Facultad de Medicina. Universidad Nacional de Colombia. Clinica Universitaria Colombia, Clínica Colsanitas, Colombia

    2 shared publications
  • Christopher Lee

    Taylor’s School of Medicine, Petaling Jaya, Malaysia

    2 shared publications
  • Erlina Burhan

    Faculty of Medicine Universitas Indonesia, RSUP Persahabatan, Jakarta, Indonesia

    2 shared publications
  • Guy Thwaites

    Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, and The Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

    2 shared publications

Latest Publications

  • Open Access

    Pertussis in Southeast Asia: country-level burden and recommendations from the Global Pertussis Initiative

    by Phung Nguyen The Nguyen, Ulrich Heininger, Rudzani Muloiwa, Carl Heinz Wirsing von König, Daniela Hozbor, Anna Ong-Lim, Tina Q. Tan, Kevin Forsyth


  • Open Access

    Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic

    by Rontgene Solante, Carlos Alvarez-Moreno, Erlina Burhan, Suwat Chariyalertsak, Nan-Chang Chiu, Sunate Chuenkitmongkol, D. V. Dung, Kao-Pin Hwang, Javier Ortiz Ibarra, Sasisopin Kiertiburanakul, et al.

    COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains ...


  • Open Access

    Invasive meningococcal disease in Malaysia, Philippines, Thailand, and Vietnam: An Asia-Pacific expert group perspective on current epidemiology and vaccination policies

    by Usa Thisyakorn, Josefina Carlos, Tawee Chotpitayasunondh, Tran M. Dien, Maria Liza A. M. Gonzales, Nguyen T. L. Huong, Zulkifli Ismail, Musa M. Nordin, Anna Lisa T. Ong-Lim, Terapong Tantawichien, et al.

    Invasive meningococcal disease (IMD) imposes a significant burden on the global community due to its high case fatality rate (4-20%) and the risk of long-term sequelae for one in five survivors. An expert group meeting was held to discuss the epidemiology of IMD and immunization policies in Malaysia, Philippines, Thailand, and Vietnam. Most of these countries do not include meningococcal immunization in their routine vaccination programs, except for high-risk groups such as immunocompromised people and pilgrims. It is difficult to estimate the epidemiology of IMD in the highly diverse Asia-Pacific region, but available evidence indicate serogroup B is increasingly dominant. Disease surveillance systems differ by country. IMD is not a notifiable disease in some of them. Without an adequate surveillance system in the region, the risk and the burden of IMD might well be underestimated. With the availability of new combined meningococcal vaccines and the World Health Organization roadmap to defeat bacterial meningitis by 2030, a better understanding of the epidemiology of IMD in the Asia-Pacific region is needed.


  • Open Access

    Expert Review of Global Real-World Data on COVID-19 Vaccine Booster Effectiveness & Safety During the Omicron-dominant Phase of the Pandemic

    by Rontgene Solante, Carlos Alvarez-Moreno, Erlina Burhan, Suwat Chariyalertsak, Nan-Chang Chiu, Sunate Chuenkitmongkol, Do Van Dung, Kao-Pin Hwang, Javier Ortiz Ibarra, Sasisopin Kiertiburanakul, et al.

    Introduction COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron (B.1.1.529) variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently-available vaccines and prompted debate about potential future vaccination strategies. Areas covered Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE data were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently-available COVID-19 vaccines. Expert opinion Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that time. The positive risk-benefit ratio of these vaccines is well established, thus increasing confidence in administering additional doses as required. Future vaccination strategies will likely include a combination of schedules based on a person’s risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population.

  • Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study

    by Maria Rosario Z Capeding, Salvacion R. Gatchalian, Mitzi Aseron, Anna Lena L. Lopez, Delia C. Yu, Maria E. Garcia Ibe, Maria Nerissa De Leon, Margaret Modequillo, Mervin Edcel E. Flavier, Anna Lisa Ong-Lim

    This study aimed to assess the safety of a fully liquid DTwP-HBV/Hib pentavalent vaccine (EupentaTM) based on the occurrence of adverse events (AEs) following vaccination.This was a prospective, op...


  • Open Access

    What is the true burden of diphtheria, tetanus, pertussis and poliovirus in children aged 3–18 years in Asia? A systematic literature review.

    by Lindsay Nicholson, Elizabeth Adkins, Mulya Rahma Karyanti, Anna Ong-Lim, Bhaskar Shenoy, Catherine Huoi, Juan C. Vargas-Zambrano


  • Open Access

    Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants

    by Johnna Perdrizet, Emily K. Horn, Winniefer Nua, Judith Perez-Peralta, Jennifer Nailes, Jaime Santos, Anna Ong-Lim

    Introduction The Philippines pediatric national immunization program (NIP) included the 13-valent pneumococcal conjugate vaccine manufactured by Pfizer (PCV13-PFE) since 2015. Uptake has been slow in particular regions, with coverage only reaching all regions in 2019. Given affordability challenges in the context of higher coverage, this study seeks to determine whether universal coverage across all regions of the Philippines with PCV13-PFE will provide good value for money compared with 10-valent PCV alternatives manufactured by GlaxoSmithKline (PCV10-GSK) or Serum Institute of India (PCV10-SII). Methods A decision analytic model is adapted for this cost-effectiveness analysis in the Philippines. Clinical and economic input parameters are taken from published sources. Future disease is predicted using age-stratified and population-level observed serotype dynamics. Total cases of pneumococcal disease, deaths, direct and indirect healthcare costs, and quality-adjusted life years (QALYs) gained are discounted 7% annually and modeled for each PCV. Given clinical uncertainty, PCV10-SII outcomes are reported as ranges. Incremental cost-effectiveness ratios (ICERs) are calculated for PCV13-PFE versus lower-valent PCVs (PCV10-GSK or PCV10-SII) from a societal perspective over 10 years. Results Nationwide PCV13-PFE use over 10 years is estimated to avert 375,831 more cases, save 53,189 additional lives, and gain 153,349 QALYs compared with PCV10-GSK. This equates to cost-savings of PHP 12.27 billion after vaccine costs are accounted for. Similarly, PCV13-PFE is more effective and cost-saving compared with PCV10-SII. Switching programs to PCV10-SII would result in more cases of disease (313,797 – 666,889), more deaths (22,759 – 72,435), and lost QALYs (108,061 – 266,108), equating to a net economic loss (PHP 359.82 million – 14.41 billion). PCV13-PFE remains cost-effective in the presence of parameter uncertainty. Conclusion PCV13-PFE would prevent exceedingly more cases and deaths compared with lower-valent PCVs. Additionally, the PCV13-PFE program is estimated to continue providing cost-savings, offering the best value for money to achieve universal PCV coverage in the Philippines.


  • Open Access

    A Narrative Review of Pneumococcal Disease in Children in the Philippines

    by Amgad Gamil, Miriam Y. Lalas, Maria Rosario Z. Capeding, Anna Lisa T. Ong-Lim, Mary Ann C. Bunyi, Angelica M. Claveria

    This narrative review describes the epidemiology of invasive pneumococcal diseases, nasopharyngeal carriage, and antibiotic resistance of Streptococcus pneumoniae serotypes, and vaccination coverage in children in the Philippines. Epidemiological data show that, despite the availability of the free-of-cost 13-valent pneumococcal conjugate vaccine for infants as part of the National Immunization Program, the burden of pneumococcal disease in young children remains high in the Philippines. The significant variability in data reported between studies highlights an urgent need for active and comprehensive disease surveillance for more accurate estimates of pneumococcal disease in the country. Although data from 2001 to 2013 show high rates of pneumococcal carriage in children in the Philippines aged < 5 years, contemporary data are lacking, again emphasizing the need for active surveillance programs. The introduction of pneumococcal conjugate vaccines has resulted in substantial declines in disease caused by pneumococcal serotypes included in the vaccines, but the emergence of pneumococcal disease due to nonvaccine serotypes is an ongoing concern. Surveillance of actively circulating serotypes is critical to better understand vaccine coverage. Antimicrobial resistance of S. pneumoniae remains a significant threat to public health worldwide; data regarding antibiotic resistance in young children in the Philippines are limited, but reports generally show low rates of antibiotic resistance in this group. National immunization rates have increased in recent years, yet many individuals are still unprotected from pneumococcal disease. Overall, there is a critical need for contemporary and accurate disease surveillance in the Philippines. Such data would provide better estimates of pneumococcal disease incidence, serotype distribution, and antibiotic resistance to better inform vaccination strategies and to ensure that children in the Philippines are best protected against pneumococcal disease.